Cosmos Health earnings release, August 20, 2026

Cosmos Health Inc. (COSM) · Form 8-K, Item 2.02 · Filed · SEC filing

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway

CHICAGO, IL / GLOBE NEWSWIRE / August 19, 2026 /

Cosmos Health Inc.

("Cosmos Health" or the "Company")

(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the second quarter and six months ended June 30, 2026.

Second Quarter and First Half 2026 Financial Highlights

Income Statement

Cosmos Health delivered its highest second-quarter and first-half revenue in Company history, with growth contributed by every core division. Decahedron nearly doubled its revenue in the United Kingdom, Cana Laboratories built its contract manufacturing orderbook to an all-time high of over 25 million units, CosmoFarm added more than 75 new pharmacies to its distribution network, and the Company's proprietary brands — including Sky Premium Life, C-Sept and C-Scrub — continued their international expansion.

Balance Sheet

Cosmos Health strengthened its capital structure during the first half of 2026, reducing total liabilities for a second consecutive quarter while lifting stockholders' equity and improving working capital efficiency, with receivables and inventory both declining against nearly 30% revenue growth on improved collections and more disciplined inventory management.

Share Repurchase Program

On June 26, 2026, the Company's Board of Directors authorized a share repurchase program of up to $5.0 million, expiring December 31, 2026 and renewable at the Company's sole discretion. Cosmos Health repurchased 2,650,000 shares for approximately $513,000 during the second quarter, and open market purchases have continued into Q3 2026, bringing total repurchases as of this date to 5,112,000 shares for approximately $1.11 million.

Q2 2026 Business Highlights

Commercial Expansion

United States Expansion

Contract Manufacturing

Clinical Validation and New Categories

R&D and Innovation

Corporate and Capital Structure

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated:

"Q2 2026 was a record second quarter, with revenue of $18.99 million, up 29% year-over-year, capping a record first half of $36.91 million. On an adjusted basis, this represents an annualized revenue run-rate in excess of $75 million — a new milestone for Cosmos, and one achieved before any impact from potential acquisitions or from second-half seasonality, which was materially stronger last year and which we expect again this year. Every core division contributed: CosmoFarm added over 75 pharmacies, Cana built its contract manufacturing orderbook to over 25 million units, and Decahedron nearly doubled its revenue in the United Kingdom.

Our proprietary brands continued to gain ground. Sky Premium Life extended its reach across Europe and the UAE through new distribution agreements. C-Scrub and C-Sept continued to build momentum, with C-Sept PRO gaining traction across leading Greek hospital groups, and C-Scrub cleared EN 12791 for surgical hand disinfection — opening the hospital and surgical channels as well as an entirely new vertical for us in animal health.

During the quarter we also took our U.S. expansion from concept to execution with the 18 Series, a portfolio we are building toward 18 clinically validated products spanning liver health, joint and inflammation support, cardiovascular health, men's wellness and healthy aging, among other areas. Supported by local manufacturing, we expect the United States to become one of our principal growth engines.

Equally important is how we achieved this growth. Adjusted gross profit rose 58% in the quarter with adjusted gross margin expanding 165 basis points, operating expenses grew at little more than half the rate of revenue, and we reduced both receivables and inventory while revenue grew nearly 30%. That is the operating leverage we have been building toward, and we are investing to extend it — a new capsule production line at Cana, robotic automation and AI systems at CosmoFarm, and AI integration across order management, warehousing and supply chain, where we see scope to reduce certain operating expenses further.

We also cut total liabilities by $6.3 million since year-end, lifting stockholders' equity 12% to $20.7 million and improving our liabilities-to-assets ratio by 550 basis points. Separately, we began buying back our own stock because we believe our shares trade well below the underlying value of our diversified asset base and growth prospects.

Moving forward, we are starting to see the benefits of economies of scale and vertical integration, and we expect increased efficiencies to play an important role as we progress toward sustained profitability. That momentum carries into Q3 2026 across every core segment, with our U.S. platform beginning to contribute."

Financial statements

Income Statement

Three Months Ended June 30, — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
GAAP FIGURESREVENUE18,986,37614,745,70236,914,26828,458,230
GAAP FIGURESGROSS PROFIT1,511,6621,163,8142,892,8333,213,613
GAAP FIGURESTOTAL OPERATING EXPENSES4,437,2693,809,1338,002,6196,692,077
GAAP FIGURESGAIN (LOSS) FROM OPERATIONS-2,925,607-2,645,319-5,109,786-3,478,464
GAAP FIGURESTOTAL OTHER INCOME (EXPENSE), NET-3,160,915-182,749-3,782,159-167,701
GAAP FIGURESNET LOSS-6,086,522-2,828,068-8,891,945-3,646,165
NON-GAAP FIGURES*ADJUSTED REVENUE19,318,30214,745,70237,716,79628,458,230
NON-GAAP FIGURES*ADJUSTED GROSS PROFIT1,843,5881,163,8143,695,3613,213,613
NON-GAAP FIGURES*ADJUSTED EBITDA-1,130,888-1,312,280-1,719,040-1,139,948
NON-GAAP FIGURES*ADJUSTED NET INCOME (LOSS)-1,687,511-1,595,307-2,652,219-1,518,756

Income Statement

Three Months Ended June 30,

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
(in $)REVENUE18,986,37614,745,70236,914,26828,458,230
(in $)Sales discount reversal331,926802,528
(in $)ADJUSTED REVENUE19,318,30214,745,70237,716,79628,458,230
(in $)GROSS PROFIT1,511,6621,163,8142,892,8333,213,613
(in $)Sales discount reversal331,926802,528
(in $)ADJUSTED GROSS PROFIT1,843,5881,163,8143,695,3613,213,613
(in $)INCOME (LOSS) BEFORE INCOME TAXES-6,086,522-2,828,068-8,891,945-3,646,165
Adjustments (add back):Depreciation and amortization expense349,181353,862697,360674,301
Adjustments (add back):Interest (income) / expense, net556,623283,027933,179378,808
Adjustments (add back):EBITDA-5,180,717-2,191,179-7,261,405-2,593,056
Adjustments (add back):Sales discount reversal331,926802,528
Adjustments (add back):Non-recurring and extraordinary items554,753376,157796,215504,584
Adjustments (add back):Stock based compensation558,858603,0201,094,6441,159,632
Adjustments (add back):Other (income) / expense, net-37,97942,190-479,041110,327
Adjustments (add back):(Gain) / loss on equity investments, net-3,650-2,6397,602-5,781
Adjustments (add back):Non-cash interest expense / Change in fair value of convertible notes2,785,787302,6952,936,657302,695
Adjustments (add back):Change in fair value of derivative liability-577,347-809,315
Adjustments (add back):Gain/(Loss) on digital assets404,145846,584
Adjustments (add back):Foreign currency transaction, net33,336-442,524346,493-618,348
Adjustments (add back):ADJUSTED EBITDA-1,130,888-1,312,280-1,719,040-1,139,948
Adjustments (add back):Interest income / (expense), net-556,623-283,027-933,179-378,808
Adjustments (add back):ADJUSTED NET INCOME-1,687,511-1,595,307-2,652,219-1,518,756

Balance Sheet

June 30, 2026 — CONDENSED CONSOLIDATED BALANCE SHEET DATA

June 30, 2026 – (Unaudited)March 31, 2026 – (Unaudited)December 31, 2025 – (Audited)
ASSETSCash & cash equivalents2,445,1682,158,9213,459,893
ASSETSInventory4,518,5605,650,4585,778,142
ASSETSAccounts receivable, prepaid expenses and other current assets29,217,38828,594,75228,662,583
ASSETSProperty and equipment, net10,140,15010,280,20310,578,858
ASSETSGoodwill and intangible assets, net6,965,9347,225,0117,569,695
ASSETSLoans receivable3,472,9163,605,3883,633,839
ASSETSOther noncurrent assets4,701,8384,854,2785,794,508
ASSETSTOTAL ASSETS61,461,95462,369,01165,477,518
LIABILITIES AND STOCKHOLDERS' EQUITYAccounts payable and accrued expenses15,297,62515,689,06117,412,973
LIABILITIES AND STOCKHOLDERS' EQUITYOther current liabilities6,760,6216,701,0516,047,940
LIABILITIES AND STOCKHOLDERS' EQUITYLines of credit8,745,8077,856,2089,177,684
LIABILITIES AND STOCKHOLDERS' EQUITYNotes payable7,075,6339,954,81211,485,084
LIABILITIES AND STOCKHOLDERS' EQUITYOther non-current and finance/lease liabilities2,907,7852,341,5202,929,208
LIABILITIES AND STOCKHOLDERS' EQUITYStockholders' and mezzanine equity20,674,48319,826,35918,424,629
LIABILITIES AND STOCKHOLDERS' EQUITYTOTAL LIABILITIES AND STOCKHOLDERS'/MEZZANINE EQUITY61,461,95462,369,01165,477,518

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Cosmos Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.